rs556794126
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000102.4(CYP17A1):c.1438_1439insATCC(p.Pro480HisfsTer27) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000047 in 1,594,208 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000050 ( 0 hom. )
Consequence
CYP17A1
NM_000102.4 frameshift
NM_000102.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.75
Genes affected
CYP17A1 (HGNC:2593): (cytochrome P450 family 17 subfamily A member 1) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. It has both 17alpha-hydroxylase and 17,20-lyase activities and is a key enzyme in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens. Mutations in this gene are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism, and adrenal hyperplasia. [provided by RefSeq, Jul 2008]
WBP1L (HGNC:23510): (WW domain binding protein 1 like) Predicted to enable ubiquitin protein ligase binding activity. Predicted to act upstream of or within CXCL12-activated CXCR4 signaling pathway; hemopoiesis; and positive regulation of protein ubiquitination. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0583 CDS is truncated, and there are 2 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 10-102830790-G-GGGAT is Pathogenic according to our data. Variant chr10-102830790-G-GGGAT is described in ClinVar as [Likely_pathogenic]. Clinvar id is 1777.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP17A1 | NM_000102.4 | c.1438_1439insATCC | p.Pro480HisfsTer27 | frameshift_variant | 8/8 | ENST00000369887.4 | NP_000093.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP17A1 | ENST00000369887.4 | c.1438_1439insATCC | p.Pro480HisfsTer27 | frameshift_variant | 8/8 | 1 | NM_000102.4 | ENSP00000358903 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152160Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152160
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000252 AC: 6AN: 237994Hom.: 0 AF XY: 0.0000311 AC XY: 4AN XY: 128802
GnomAD3 exomes
AF:
AC:
6
AN:
237994
Hom.:
AF XY:
AC XY:
4
AN XY:
128802
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000499 AC: 72AN: 1442048Hom.: 0 Cov.: 27 AF XY: 0.0000599 AC XY: 43AN XY: 717764
GnomAD4 exome
AF:
AC:
72
AN:
1442048
Hom.:
Cov.:
27
AF XY:
AC XY:
43
AN XY:
717764
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152160Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74338
GnomAD4 genome
AF:
AC:
3
AN:
152160
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74338
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 21, 2023 | This sequence change creates a premature translational stop signal (p.Pro480Hisfs*27) in the CYP17A1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 29 amino acid(s) of the CYP17A1 protein. This variant is present in population databases (rs556794126, gnomAD 0.005%). This premature translational stop signal has been observed in individuals with congenital adrenal hyperplasia (PMID: 1577471, 2786493). ClinVar contains an entry for this variant (Variation ID: 1777). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 23, 2017 | The c.1435_1438dupATCC variant has been reported previously in the homozygous state in association with 17 alpha-hydroxylase/17,20-lyase deficiency (Kagimoto et al., 1988; Kagimoto et al., 1989; Imai et al., 1992). The duplication causes a frameshift starting with codon Proline 480, changes this amino acid to a Histidine residue and creates a premature Stop codon at position 27 of the new reading frame, denoted p.Pro480HisfsX27. This variant is predicted to cause loss of normal protein function through protein truncation. The variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). In summary, we consider this variant to be pathogenic. - |
Likely pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Deficiency of steroid 17-alpha-monooxygenase Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 09, 2018 | The p.Pro480HisfsX27 variant in CYP17A1 has been reported in 7 individuals with 17 alpha-hydroxylase/17,20-lyase deficiency and segregated with disease in 2 aff ected family members from 2 families (Kagimoto 1988, Kagimoto 1989, Imai 1992). It has also been identified in 5/104972 of European chromosomes by gnomAD (http: //gnomad.broadinstitute.org). This variant is predicted to cause a frameshift, w hich alters the protein?s amino acid sequence beginning at position 480 and lead s to a premature termination codon 27 amino acids downstream. This termination c odon occurs within the terminal 50 bases of the second to the last exon and is t herefore likely to escape nonsense mediated decay (NMD) and result in a truncate d protein. In summary, although additional studies are required to fully establi sh its clinical significance, the p.Pro480HisfsX27 variant is likely pathogenic. ACMG/AMP criteria applied: PM2, PM3, PVS1_Moderate, PP1_Moderate. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 09, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 11, 2024 | - - |
17-alpha-hydroxylase/17,20-lyase deficiency, combined complete Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 1992 | - - |
Congenital adrenal hyperplasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 20, 2022 | Variant summary: CYP17A1 c.1435_1438dupATCC (p.Pro480HisfsX27) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2.5e-05 in 237994 control chromosomes. c.1435_1438dupATCC has been reported in the literature in multiple individuals affected with Congenital Adrenal Hyperplasia (example Kagimoto_1988, Kagimoto-1989, Perez_2004). These data indicate that the variant is very likely to be associated with disease. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation.Two laboratories classified the variant as pathogenic, one as likely pathogenic, and one classified it VUS. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at